Compare Citius Pharmaceuticals Inc (CTXR) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NextEra Energy, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while NextEra Energy, Inc. trades at $77.35 (market cap $161.39B). The key difference: NextEra Energy, Inc. is far larger — about 11849.5× Citius Pharmaceuticals Inc's market cap, and NextEra Energy, Inc. pays a 3.22% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and NextEra Energy, Inc. for 83 Days on average.
| CTXR | NEE | |
|---|---|---|
Market Cap | $13.62M | $161.39B |
Volume | 132,438 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $1.82 | $97.88 |
52-Week Low | $0.48 | $75.49 |
Typical Hold Time | 16 Days | 83 Days |
Enterprise Value | $3.79M | $268.72B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
NextEra Energy (NEE) trades at $77.34, up 0.36% on the day, with a bearish technical signal but strong analyst support. The stock is near a 52-week low, with key support at $76. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains robust profitability with a 32.4% net margin and is pursuing growth through projects like the $22.3 billion Project Star energy campus.
The outlook is cautiously optimistic, with a consensus price target of $96 offering 24% upside. Risks include high debt levels and interest rate sensitivity, but strong cash flow and a 66.7% buy rating from analysts suggest long-term value. Investors should weigh growth initiatives against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
